Liquidia Corporation has announced its financial results for the third quarter of 2026, showcasing a significant increase in sales and a resolution of ongoing litigation. The company's performance highlights its strong market position in the pharmaceutical preparations sector.
On November 10, 2026, Liquidia Corporation, a Delaware-based biopharmaceutical company, reported net product sales of $222.7 million for its YUTREPIA inhalation powder. This marks a 31% increase from the previous quarter. The company also noted that total patient shipments reached their highest monthly level since the product's launch.
Liquidia is primarily focused on developing innovative therapies for patients with challenging respiratory and vascular diseases. The company trades under the ticker symbol LQDA on the Nasdaq exchange. Its recent filings include a Form 10-Q submitted on the same day as the 8-K, indicating ongoing transparency in its financial reporting.
The filing reveals that the company resolved all litigation with United Therapeutics through a global settlement, ensuring continuity of care for patients using YUTREPIA. This resolution allows Liquidia to concentrate fully on its business growth and product development.
In addition to the sales growth, Liquidia reported a net loss of $236.3 million, which includes a significant charge of $389.7 million related to the litigation settlement. Despite this loss, the company recorded its fifth consecutive quarter of increasing non-GAAP adjusted EBITDA, reaching $140.5 million.
Dr. Roger Jeffs, Liquidia’s CEO, emphasized the strong market acceptance of YUTREPIA among physicians, noting its preferred product profile due to the control and flexibility it offers in patient therapy. He expressed confidence in the company’s ability to advance its pipeline of inhaled therapies, which includes studies for new indications where patients currently lack approved options.
The filing also included an updated corporate presentation intended for healthcare conferences and analysts, reflecting Liquidia's commitment to maintaining investor relations and transparency.
This update from Liquidia Corp signifies a positive trajectory for the company and the broader pharmaceutical preparations industry. As competitors observe Liquidia's success, they may need to adapt their strategies to maintain their market positions in an increasingly competitive landscape.
The next steps for Liquidia remain unclear, as the filing does not specify any upcoming votes or additional filings. However, the company is expected to continue focusing on its product offerings and market expansion efforts.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










